Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
All articles
Showing 373–384 of 411 articles
- Interpret the evidence
Why a smaller waist did not establish improved cognition in an HIV trial
Tesamorelin is a 44-residue analogue of growth hormone–releasing hormone with a chemical group attached at its starting end. An older randomized trial asked whether tesamorelin changed thinking and memory measures in adults with HIV, abdominal obesity and neurocognitive impairment.
Tesamorelin2 sources (2025, 2026)
- Check methods and identity
What a liver-fat trial measured beyond abdominal fat
Tesamorelin is a chemically modified, 44-residue analogue of growth hormone–releasing hormone that stimulates the pituitary. An older trial asked whether the drug affected fat stored in the liver in adults with HIV and fatty liver disease.
Tesamorelin2 sources (2019, 2026)
- Explore study findings
What a randomized extension showed when participants switched to placebo
Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with an added chemical group at its starting end. An older clinical trial used a second randomized phase to ask what happened to abdominal visceral fat when participants continued the study treatment or switched to placebo.
Tesamorelin2 sources (2010, 2026)
- Explore study findings
What a Large Sepsis Trial Found About Thymosin Alpha 1
Thymosin alpha-1 is a 28-amino-acid peptide studied in immune regulation, and thymalfasin is a drug form of it. The phase 3 TESTS trial asked whether adding thymosin alpha-1 to the care of adults with sepsis reduced death within 28 days.
Thymosin Alpha-13 sources (2025, 2026)
- Check methods and identity
What a 2026 Thymalfasin Sepsis Registry Entry Plans to Measure
Thymosin alpha-1 is an immune-related peptide, and thymalfasin is its drug form. An October 2026 trial registration describes a study in adults with sepsis and signs of reduced immune function. It records a research plan and does not report a result.
Thymosin Alpha-11 source (2026)
- Interpret the evidence
Why Lymphocyte Counts Cannot Tell the Whole Story in Cancer Research
Thymosin alpha-1 is a peptide investigated in this context. A 2025 study examined blood counts in people with advanced cancer who received thymosin alpha-1 before a regimen involving radiation and immunotherapy. Its publication falls within the requested year.
Thymosin Alpha-11 source (2025)
- Understand the science
How a 2026 Study Linked Thymosin Alpha 1 to Immune Recognition in Mice
Thymosin alpha-1 is a peptide studied for effects on immunity. A 2026 study by Yiting Wei and colleagues examined why certain immune responses to tumors were weak after chemotherapy. The paper combined observations from human samples with experiments in cells and mice.
Thymosin Alpha-11 source (2026)
- Interpret the evidence
What a Thymalfasin Vaccine Study Registration Can and Cannot Show
Thymosin alpha-1 is an immune-related peptide, and thymalfasin is a defined drug form. A registry record updated in 2026 describes a study involving older adults receiving a COVID-19 vaccine booster.
Thymosin Alpha-11 source (2026)
- Check methods and identity
Why Thymosin Alpha 1 Needs Its Own Identity and Regulatory Evidence
Thymosin alpha-1 is a 28-amino-acid peptide studied in immune biology. It is distinct from thymosin beta-4 and from materials described as fragments of beta-4. An article about one should not inherit the clinical or regulatory evidence for the other.
Thymosin Alpha-13 sources (2024, 2026)
- Check methods and identity
What the Japanese tirzepatide trial measured around the abdomen
Tirzepatide is a modified peptide that activates GIP and GLP-1 receptors. The “GLP-2” in this catalog label is an identifier and does not describe tirzepatide’s receptor targets.
TIRZ GLP-21 source (2026)
- Explore study findings
What the lowest recorded weight adds to a three-year analysis
Tirzepatide acts at GIP and GLP-1 receptors. The “TIRZ GLP-2” catalog wording refers to tirzepatide rather than the GLP-2 receptor. A 2026 analysis explored how much weight participants regained from their lowest recorded weight while they remained in a long-term study.
TIRZ GLP-22 sources (2022, 2026)
- Interpret the evidence
Why an early weight response did not tell the whole story
Tirzepatide is a peptide that activates GIP and GLP-1 receptors. “TIRZ GLP-2” is the catalog’s wording for this molecule. A 2026 analysis asked how participants’ early weight changes related to their outcomes at a later visit.
TIRZ GLP-22 sources (2022, 2026)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
